Vaccine efficacy of fusogenic liposomes containing tumor cell-lysate against murine B16BL6 melanoma.
Recent advances in tumor immunology have facilitated the development of cancer immunotherapy targeting tumor-associated antigens (TAAs). However, because TAAs were identified in only a few types of human cancer, novel vaccine strategies that utilize tumor cell-lysate (TCL), including unidentified TAAs as an antigen source, are needed. Herein, we describe the utility of fusogenic liposomes (FLs) as TCL-delivery carriers for both ex vivo dendritic cell-based vaccination and in vivo direct immunization in the murine B16BL6 melanoma model. As a result, both in vivo direct immunization and ex vivo immunization induced anti-B16 melanoma prophylactic effects. Ex vivo dendritic cell (DC)-mediated vaccination strategy exert more potent anti-tumor effect than direct immunization. Our results suggest that this flexible system is a promising approach for the development of versatile cancer immunotherapy regimes.
Yoshikawa
Tomoaki
T
Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Osaka University.
Okada
Naoki
N
Tsujino
Masaki
M
Gao
Jian-Qing
JQ
Hayashi
Akira
A
Tsutsumi
Yasuo
Y
Mayumi
Tadanori
T
Yamamoto
Akira
A
Nakagawa
Shinsaku
S
D000818:Animals; D017951:Antigen Presentation; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000276:immunology; D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000494:pharmacology*; D003593:Cytoplasm / Q000276:immunology; D003713:Dendritic Cells / Q000276:immunology; D004337:Drug Carriers; D007114:Immunization; D008081:Liposomes; D008546:Melanoma, Experimental / Q000276:immunology* / Q000473:pathology / Q000517:prevention & control*; D051379:Mice; D008810:Mice, Inbred C57BL; D009368:Neoplasm Transplantation; D010047:Ovalbumin / Q000276:immunology; D029082:Sendai virus / Q000276:immunology
D015295:Antigens, Tumor-Associated, Carbohydrate; D019496:Cancer Vaccines; D004337:Drug Carriers; D008081:Liposomes; D010047:Ovalbumin